These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1003 related items for PubMed ID: 17242925

  • 1. Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.
    Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD.
    Psychopharmacology (Berl); 2007 Feb; 190(3):373-82. PubMed ID: 17242925
    [Abstract] [Full Text] [Related]

  • 2. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.
    Bortolozzi A, Díaz-Mataix L, Toth M, Celada P, Artigas F.
    Psychopharmacology (Berl); 2007 Apr; 191(3):745-58. PubMed ID: 17265076
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.
    Wood MD, Scott C, Clarke K, Cato KJ, Patel N, Heath J, Worby A, Gordon L, Campbell L, Riley G, Davies CH, Gribble A, Jones DN.
    CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):445-52. PubMed ID: 16918396
    [Abstract] [Full Text] [Related]

  • 4. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.
    Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA.
    Eur J Pharmacol; 2002 Apr 26; 441(3):137-40. PubMed ID: 12063084
    [Abstract] [Full Text] [Related]

  • 5. F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.
    Newman-Tancredi A, Assié MB, Martel JC, Cosi C, Slot LB, Palmier C, Rauly-Lestienne I, Colpaert F, Vacher B, Cussac D.
    Br J Pharmacol; 2007 May 26; 151(2):237-52. PubMed ID: 17375087
    [Abstract] [Full Text] [Related]

  • 6. In vitro profile of the antidepressant candidate OPC-14523 at rat and human 5-HT1A receptors.
    Jordan S, Chen R, Koprivica V, Hamilton R, Whitehead RE, Tottori K, Kikuchi T.
    Eur J Pharmacol; 2005 Jul 11; 517(3):165-73. PubMed ID: 15985260
    [Abstract] [Full Text] [Related]

  • 7. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.
    McCreary AC, Glennon JC, Ashby CR, Meltzer HY, Li Z, Reinders JH, Hesselink MB, Long SK, Herremans AH, van Stuivenberg H, Feenstra RW, Kruse CG.
    Neuropsychopharmacology; 2007 Jan 11; 32(1):78-94. PubMed ID: 16710314
    [Abstract] [Full Text] [Related]

  • 8. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.
    Dahan L, Husum H, Mnie-Filali O, Arnt J, Hertel P, Haddjeri N.
    J Psychopharmacol; 2009 Mar 11; 23(2):177-89. PubMed ID: 18515444
    [Abstract] [Full Text] [Related]

  • 9. Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924.
    Newman-Tancredi A, Rivet JM, Cussac D, Touzard M, Chaput C, Marini L, Millan MJ.
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Sep 11; 368(3):188-99. PubMed ID: 12923612
    [Abstract] [Full Text] [Related]

  • 10. Effects of the potential antidepressant OPC-14523 [1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2-quinolinone monomethanesulfonate] a combined sigma and 5-HT1A ligand: modulation of neuronal activity in the dorsal raphe nucleus.
    Bermack JE, Haddjeri N, Debonnel G.
    J Pharmacol Exp Ther; 2004 Aug 11; 310(2):578-83. PubMed ID: 15044555
    [Abstract] [Full Text] [Related]

  • 11. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
    Kiss B, Horváth A, Némethy Z, Schmidt E, Laszlovszky I, Bugovics G, Fazekas K, Hornok K, Orosz S, Gyertyán I, Agai-Csongor E, Domány G, Tihanyi K, Adham N, Szombathelyi Z.
    J Pharmacol Exp Ther; 2010 Apr 11; 333(1):328-40. PubMed ID: 20093397
    [Abstract] [Full Text] [Related]

  • 12. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C, Carilla-Durand E, Assié MB, Ormiere AM, Maraval M, Leduc N, Newman-Tancredi A.
    Eur J Pharmacol; 2006 Mar 27; 535(1-3):135-44. PubMed ID: 16554049
    [Abstract] [Full Text] [Related]

  • 13. SB-272183, a selective 5-HT(1A), 5-HT(1B) and 5-HT(1D) receptor antagonist in native tissue.
    Watson J, Roberts C, Scott C, Kendall I, Collin L, Day NC, Harries MH, Soffin E, Davies CH, Randall AD, Heightman T, Gaster L, Wyman P, Parker C, Price GW, Middlemiss DN.
    Br J Pharmacol; 2001 Jul 27; 133(6):797-806. PubMed ID: 11454652
    [Abstract] [Full Text] [Related]

  • 14. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms.
    Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J.
    Biochem Pharmacol; 2006 Feb 14; 71(4):521-9. PubMed ID: 16336943
    [Abstract] [Full Text] [Related]

  • 15. In vivo electrophysiological assessment of the putative antidepressant Wf-516 in the rat raphe dorsalis, locus coeruleus and hippocampus.
    El Mansari M, Blier P.
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Jan 14; 376(5):351-61. PubMed ID: 18060386
    [Abstract] [Full Text] [Related]

  • 16. SB-649915, a novel, potent 5-HT1A and 5-HT1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue.
    Scott C, Soffin EM, Hill M, Atkinson PJ, Langmead CJ, Wren PB, Faedo S, Gordon LJ, Price GW, Bromidge S, Johnson CN, Hagan JJ, Watson J.
    Eur J Pharmacol; 2006 Apr 24; 536(1-2):54-61. PubMed ID: 16571351
    [Abstract] [Full Text] [Related]

  • 17. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
    Li Z, Ichikawa J, Dai J, Meltzer HY.
    Eur J Pharmacol; 2004 Jun 16; 493(1-3):75-83. PubMed ID: 15189766
    [Abstract] [Full Text] [Related]

  • 18. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile.
    Claustre Y, Peretti DD, Brun P, Gueudet C, Allouard N, Alonso R, Lourdelet J, Oblin A, Damoiseau G, Françon D, Suaud-Chagny MF, Steinberg R, Sevrin M, Schoemaker H, George P, Soubrié P, Scatton B.
    Neuropsychopharmacology; 2003 Dec 16; 28(12):2064-76. PubMed ID: 12902994
    [Abstract] [Full Text] [Related]

  • 19. Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats.
    Marona-Lewicka D, Nichols DE.
    Psychopharmacology (Berl); 2004 Apr 16; 172(4):415-21. PubMed ID: 14647959
    [Abstract] [Full Text] [Related]

  • 20. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator.
    Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mørk A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbøl TB, Kikuchi T.
    J Pharmacol Exp Ther; 2014 Sep 16; 350(3):589-604. PubMed ID: 24947465
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.